Pulmonx Corp Files 10-Q for Q2 2024
Ticker: LUNG · Form: 10-Q · Filed: Aug 2, 2024 · CIK: 1127537
| Field | Detail |
|---|---|
| Company | Pulmonx Corp (LUNG) |
| Form Type | 10-Q |
| Filed Date | Aug 2, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Pulmonx 10-Q filed: Q2 2024 financials are in, showing performance vs. last year.
AI Summary
Pulmonx Corp filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial performance and operations. Key financial data and operational highlights for the second quarter and first half of 2024 are presented, alongside comparative figures from 2023.
Why It Matters
This 10-Q filing provides investors and analysts with crucial financial and operational updates for Pulmonx Corp, impacting their understanding of the company's current health and future prospects.
Risk Assessment
Risk Level: medium — 10-Q filings are standard financial reports, but the specific content can reveal risks or opportunities impacting the company's valuation.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
- 20240802 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Pulmonx Corp (company) — Filer of the 10-Q report
- 20240630 (date) — End of the reporting period
- 20240802 (date) — Filing date of the report
FAQ
What is the primary purpose of this 10-Q filing?
This 10-Q filing provides a comprehensive quarterly financial report for Pulmonx Corp, detailing its financial condition and results of operations for the period ending June 30, 2024.
What fiscal period does this 10-Q cover?
This 10-Q filing covers the fiscal period ending on June 30, 2024.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on August 2, 2024.
What is Pulmonx Corp's Standard Industrial Classification (SIC) code?
Pulmonx Corp's SIC code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Where is Pulmonx Corp headquartered?
Pulmonx Corp is headquartered at 700 Chesapeake Drive, Redwood City, CA 94063.
Filing Stats: 4,625 words · 19 min read · ~15 pages · Grade level 17.8 · Accepted 2024-08-02 16:27:34
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share LUNG The Nasdaq Sto
Filing Documents
- lung-20240630.htm (10-Q) — 1584KB
- exhibit31_1x080224.htm (EX-31.1) — 10KB
- exhibit31_2x080224.htm (EX-31.2) — 10KB
- exhibit32_1x080224.htm (EX-32.1) — 6KB
- exhibit32_2x080224.htm (EX-32.2) — 6KB
- 0001127537-24-000077.txt ( ) — 8084KB
- lung-20240630.xsd (EX-101.SCH) — 51KB
- lung-20240630_cal.xml (EX-101.CAL) — 96KB
- lung-20240630_def.xml (EX-101.DEF) — 232KB
- lung-20240630_lab.xml (EX-101.LAB) — 713KB
- lung-20240630_pre.xml (EX-101.PRE) — 502KB
- lung-20240630_htm.xml (XML) — 1055KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION 1
Financial Statements (Unaudited)
Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Unaudited Condensed Consolidated Financial Statements 8
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 39
Controls and Procedures
Item 4. Controls and Procedures 41
OTHER INFORMATION
PART II. OTHER INFORMATION 42
Legal Proceedings
Item 1. Legal Proceedings 42
Risk Factors
Item 1A. Risk Factors 43
Unregistered Sales of Securities and Use of Proceeds
Item 2. Unregistered Sales of Securities and Use of Proceeds 100
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 100
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 100
Other Information
Item 5. Other Information 100
Exhibits
Item 6. Exhibits 101
Signatures
Signatures 103 2 Table of Contents
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial condition, business strategy, plans, and objectives of management for future operations and statements that are necessarily dependent upon future events are forward-looking statements. In some cases, you can identify forward-looking statements by words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, and assumptions, including risks described in the section entitled "Risk Factors." These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our bu
Financial Information
Part I. Financial Information
Financial Statements
Item 1. Financial Statements Pulmonx Corporation Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) (unaudited) June 30, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 63,464 $ 83,547 Restricted cash 257 237 Short-term marketable securities 51,081 33,555 Accounts receivable, net 11,080 12,105 Inventory 16,980 16,743 Prepaid expenses and other current assets 3,297 4,235 Total current assets 146,159 150,422 Long-term marketable securities — 14,390 Long-term inventory 2,300 2,580 Property and equipment, net 2,830 4,028 Goodwill 2,333 2,333 Intangible assets, net — 31 Right of use assets 18,490 3,406 Other long-term assets 515 591 Total assets $ 172,627 $ 177,781 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 3,181 $ 1,497 Accrued liabilities 11,783 16,234 Income taxes payable 66 93 Deferred revenue 107 104 Short-term debt 93 2,155 Current lease liabilities 1,071 3,074 Total current liabilities 16,301 23,157 Deferred tax liability 118 114 Long-term lease liabilities 17,914 1,106 Long-term debt 37,110 35,089 Total liabilities 71,443 59,466 Commitments and contingencies (Note 8) 1 Table of Contents Stockholders' equity Preferred stock, $ 0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value, 200,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 39,151,861 shares issued and outstanding as of June 30, 2024 and 38,516,383 shares issued and outstanding as of December 31, 2023 39 39 Additional paid-in capital 539,408 526,797 Accumulated other comprehensive income 1,973 2,640 Accumulated deficit ( 440,236 ) ( 411,161 ) Total stockholders' equity 101,184 118,315 Total liabilities and stockholders' equity $ 172,627 $ 177,781 The accompanying notes are an integral part of these unaudited interim condensed consolid